Top Page
Arvinas Holding Company
(NASDAQ:ARVN)
Arvinas Holding Company (ARVN) vs. SPDR S&P 500 ETF (SPY)
Arvinas Holding Company Business Overview & Revenue Model
Arvinas Holding Company Earnings Call Summary
Arvinas Holding Company Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 312.30M | 263.40M | 78.50M | 131.40M | 53.60M | 25.90M |
| Gross Profit | 60.60M | 263.40M | 78.50M | 131.40M | 53.60M | 21.80M |
| EBITDA | -81.70M | -243.60M | -394.80M | -255.00M | -182.40M | -117.60M |
| Net Income | -58.50M | -198.90M | -367.30M | -282.50M | -191.00M | -119.30M |
Balance Sheet | ||||||
| Total Assets | 844.30M | 1.09B | 1.30B | 1.27B | 1.58B | 717.37M |
| Cash, Cash Equivalents and Short-Term Investments | 787.60M | 1.04B | 1.26B | 1.21B | 1.50B | 688.53M |
| Total Debt | 9.30M | 9.70M | 3.20M | 5.50M | 5.00M | 4.10M |
| Total Liabilities | 279.90M | 529.70M | 644.60M | 703.90M | 799.90M | 75.11M |
| Stockholders Equity | 564.40M | 561.70M | 660.00M | 564.90M | 781.70M | 642.26M |
Cash Flow | ||||||
| Free Cash Flow | -329.50M | -261.10M | -350.70M | -280.30M | 554.70M | -96.20M |
| Operating Cash Flow | -327.50M | -259.30M | -347.80M | -273.50M | 559.40M | -89.76M |
| Investing Cash Flow | 360.70M | 34.70M | 203.50M | 242.80M | -1.31B | 164.25M |
| Financing Cash Flow | -16.90M | 7.90M | 374.70M | 4.70M | 278.60M | 504.67M |
Arvinas Holding Company Technical Analysis
Arvinas Holding Company Risk Analysis
Arvinas Holding Company Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
60 Neutral | $655.41M | ― | -37.82% | ― | -100.00% | -28.79% | |
55 Neutral | $996.78M | ― | -308.02% | ― | 196.42% | 53.92% | |
53 Neutral | $702.61M | ― | ― | ― | ― | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $690.24M | ― | -379.53% | ― | 366.84% | -35.87% | |
48 Neutral | $772.22M | ― | -32.71% | ― | ― | ― | |
46 Neutral | $545.64M | ― | -49.72% | ― | ― | 6.82% |
Arvinas Holding Company Corporate Events
Arvinas Holding Company, a clinical-stage biotechnology firm, is pioneering the development of protein degradation therapies aimed at treating debilitating diseases through its PROTAC platform. In its third-quarter 2025 earnings report, Arvinas highlighted significant progress in its clinical trials and strategic partnerships, including a collaboration with Pfizer for the commercialization of vepdegestrant, a promising cancer therapy. The company reported a decrease in revenue to $41.9 million from $102.4 million in the previous year, primarily due to the completion of agreements with Novartis and Bayer. However, Arvinas demonstrated strong financial management by reducing its research and development expenses and general administrative costs significantly. Looking ahead, Arvinas aims to continue advancing its clinical trials and partnerships, with a focus on delivering transformative therapies to patients and maintaining a robust financial position through 2028.
Arvinas Holding Company recently held its earnings call, revealing a mix of optimism and challenges. The company showcased significant progress in its clinical pipeline, particularly with ARV-102, and demonstrated financial stability. However, this was offset by a notable decline in revenue and ongoing challenges in achieving efficacious exposure levels in some trials.
Study Overview: Arvinas Holding Company is conducting a Phase 1/2 clinical trial titled A Phase 1/2 Clinical Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics of ARV-806 in Participants With KRAS G12D Mutated Advanced Solid Tumors. The study aims to assess the safety and potential anti-tumor activity of ARV-806, an investigational drug, in adults with advanced cancer featuring the KRAS G12D mutation. This research is significant as it explores a novel treatment avenue for a challenging mutation in solid tumors.
Study Overview: Arvinas Holding Company is conducting a Phase 1 clinical study titled ‘A Phase 1 First in Human Study of ARV-393 in Adult Participants With Advanced Non-Hodgkin’s Lymphoma.’ The study aims to evaluate the safety and potential anti-tumor activity of ARV-393, an investigational drug, in patients with advanced Relapsed/Refractory non-Hodgkin’s lymphoma. This study is significant as it explores a new treatment option for this challenging condition.
On October 24, 2025, Arvinas, Inc. announced preclinical data for ARV-806, a PROTAC KRAS G12D degrader, at the 2025 AACR-NCI-EORTC International Conference. The data showed ARV-806’s potential as a best-in-class therapy for KRAS G12D mutated cancers, demonstrating significant potency in degrading KRAS G12D protein and reducing cancer cell proliferation across pancreatic, colorectal, and lung cancer models. The company is currently evaluating ARV-806 in a Phase 1 clinical trial for patients with advanced solid tumors harboring KRAS G12D mutations, highlighting its potential to address high unmet needs in these cancers.
The most recent analyst rating on (ARVN) stock is a Hold with a $9.00 price target. To see the full list of analyst forecasts on Arvinas Holding Company stock, see the ARVN Stock Forecast page.
On October 20, 2025, Arvinas announced new patient-reported outcomes from its Phase 3 VERITAC-2 clinical trial for vepdegestrant, presented at the ESMO 2025 Congress. Vepdegestrant, developed with Pfizer, showed significant improvements in quality of life and delayed deterioration in patients with ESR1-mutated, ER+/HER2- advanced breast cancer compared to fulvestrant. The trial results reinforce vepdegestrant’s potential as a promising treatment option, highlighting its clinical benefits and supporting its development as a monotherapy for this patient group.
The most recent analyst rating on (ARVN) stock is a Sell with a $6.00 price target. To see the full list of analyst forecasts on Arvinas Holding Company stock, see the ARVN Stock Forecast page.
On October 5, 2025, Arvinas, Inc. announced positive Phase 1 clinical trial results for ARV-102, a PROTAC LRRK2 degrader, presented at the 2025 International Congress of Parkinson’s Disease and Movement Disorders. The trials, conducted on healthy volunteers and Parkinson’s disease patients, demonstrated that ARV-102 was well tolerated and showed dose-dependent increases in cerebrospinal fluid exposure, indicating brain penetration. Significant reductions in LRRK2 protein and pathway biomarkers were observed, supporting further development of ARV-102 for Parkinson’s disease and progressive supranuclear palsy. The company plans to present additional data in 2026 and initiate a Phase 1b trial for progressive supranuclear palsy.
The most recent analyst rating on (ARVN) stock is a Buy with a $15.00 price target. To see the full list of analyst forecasts on Arvinas Holding Company stock, see the ARVN Stock Forecast page.
On September 17, 2025, Arvinas announced a 15% workforce reduction primarily affecting roles related to the commercialization of vepdegestrant, expecting to incur $4.5 million in related costs. The company also updated its collaboration with Pfizer, agreeing to out-license vepdegestrant’s commercialization rights to a third party, aiming to optimize costs and streamline operations. Additionally, Arvinas introduced a $100 million share repurchase program, reflecting confidence in its business strength and commitment to maximizing shareholder value. These strategic actions are expected to save over $100 million annually compared to FY 2024 and extend the company’s cash runway into the second half of 2028.
The most recent analyst rating on (ARVN) stock is a Hold with a $7.50 price target. To see the full list of analyst forecasts on Arvinas Holding Company stock, see the ARVN Stock Forecast page.
On August 8, 2025, Arvinas, in collaboration with Pfizer, announced that the FDA accepted their New Drug Application for vepdegestrant, a PROTAC ER degrader, for treating ER+/HER2- ESR1-mutated advanced or metastatic breast cancer. This acceptance, based on the Phase 3 VERITAC-2 trial, marks a significant step forward as vepdegestrant demonstrated improved progression-free survival compared to fulvestrant, potentially offering a new treatment option for patients with limited alternatives after first-line therapy.
The most recent analyst rating on (ARVN) stock is a Buy with a $18.00 price target. To see the full list of analyst forecasts on Arvinas Holding Company stock, see the ARVN Stock Forecast page.
Arvinas, Inc., a clinical-stage biotechnology company based in New Haven, Connecticut, is pioneering the development of protein degradation therapies to treat debilitating and life-threatening diseases. The company focuses on targeted protein degradation using its PROTAC platform, with investigational drugs targeting various conditions, including breast cancer and neurodegenerative disorders.
Arvinas Holding Company recently held its earnings call, revealing a balanced sentiment among stakeholders. The company showcased strong clinical progress and significant collaborations, notably with Novartis, and the potential approval of vepdeg. However, these positives were countered by a decline in revenue, workforce reductions, and challenges in their partnership with Pfizer.